This animation addresses the mode of action of how Cardiac Contractility Modulation takes place at the physiologic level, including gene expression, calcium recycling, and the effects of CCM therapy on cardiac contractility.
- October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments.
Click here to Login
